Please ensure Javascript is enabled for purposes of website accessibility

Did Pfizer's No-Split Decision Cost Investors a Lot of Money?

By Keith Speights - Oct 7, 2016 at 2:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Let Pfizer be Pfizer? Staying one company could be a bad move for shareholders.

Image source: Getty Images.

Pfizer (PFE 3.59%) announced on Sept. 26 that it would remain as one company rather than split into two. The decision was made to "maximize future shareholder value creation," the company said. But could the choice to stay united end up costing investors a lot of money? 

Changing conditions

Pfizer seriously considered splitting into two publicly traded entities, with one company focused on "innovative health" (fast-growing drugs), while the other specialized in "essential health" (legacy drugs and biosimilars). The thought was that separating would release so-called "trapped value" that couldn't be achieved with all operations under one company. 

How did Pfizer make its decision? It first evaluated the performance of both business units to determine if they could compete effectively as stand-alone entities. Pfizer then assessed whether there was trapped value by keeping the business units together. The company also considered if it could execute its broader strategy more effectively under the current structure or as two separate entities.

When Pfizer first began internal discussions several years ago, the deck seemed stacked in favor of splitting. But the company maintains that conditions changed over time. Maybe at one point the sum of the valuations of each part was greater than Pfizer's combined market cap, but CFO Frank D'Amelio said that's no longer the case.

Comparisons

Investors looking at other splits might question Pfizer's decision. The company's own spin-off of its animal health business has turned out very well for shareholders. Zoetis became a separate entity from Pfizer in early 2013. Four months later, Pfizer shareholders were given the option to swap Pfizer shares for Zoetis shares at a 7% discount. Any takers on that offer would have profited handsomely.

PFE Chart

PFE data by YCharts.

But this isn't the best comparison. I'd instead look at a similar choice faced by Abbott Labs (ABT 0.71%). Back in 2011, Abbott announced plans to separate into two companies -- one focused on branded prescription drugs and the other focused on products including medical devices and generic drugs. Abbott CEO Miles White promoted the split as a move that would stir investor interest and create more value for shareholders.

White was right on target. On Jan. 2, 2013, AbbVie (ABBV -0.47%) opened its doors as a new publicly traded company. The biotech's products included blockbuster drug Humira and a strong pipeline. Here's how shares of AbbVie and Abbott have performed since then:

ABT Chart

ABT data by YCharts.

Could Pfizer have achieved these kind of results with a PfiVie spin-off? Maybe not. After all, Pfizer doesn't have a drug that matches the superstar status of Humira. However, the company's innovative health segment includes blockbuster drug Lyrica IH, which posted an impressive 19% year-over-year growth rate in the first half of 2016. Several other drugs are rising stars, with Ibrance and Xeljanz leading the way.

Acquisitions are also bolstering Pfizer's innovative health lineup. The buyout of Anacor Pharmaceuticals in June added promising atopic dermatitis drug crisaborole. Pfizer's recently completed acquisition of Medivation gives it prostate cancer drug Xtandi.

Meanwhile, Pfizer's essential health unit includes plenty of drugs with declining sales like Lipitor and Zoloft. Last year's acquisition of Hospira added injectable drugs and biosimilars, which give the essential health business segment a pathway to growth.

The right call?

Pfizer says that it can drive value more effectively for shareholders by remaining intact. By operating two units within the same corporate umbrella, Pfizer is "already accessing many of the potential benefits of a split -- sharper focus, increased accountability, and a greater sense of urgency," says CEO Ian Read. 

I don't doubt that Read is correct. However, I wonder if the company might have underappreciated the psychological boost a split could have had in the investor community. Pfizer has been something of a "blah" stock for a while now. I'm just not sure that's going to change significantly without a major splash like a split could have provided. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$113.24 (0.71%) $0.80
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$151.01 (-0.47%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.